PARP抑制剂用于铂敏感复发卵巢癌患者维持治疗的血液学毒性概述

Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer

卵巢癌是威胁女性健康和生命的重大疾病之一。近年来,聚腺苷二磷酸核糖聚合酶抑制剂[poly (ADP-ribose)polymerase inhibitors,PARPi]作为一类新型的靶向治疗药物为卵巢癌患者带来获益,并被国内外多项临床指南、规范推荐用于铂敏感复发卵巢癌患者的维持治疗及术后的维持治疗。但与此同时带来的安全性问题,尤其是血液学毒性值得关注。从作用机制、药代动力学出发,对比目前已上市的3种PARPi的特征及其血液学毒性差异,以期为复发性卵巢癌患者临床用药提供参考。

Ovarian cancer is one of the major health-and life-threatening diseases among females. In recent years, poly(ADPribose) polymerase inhibitors(PARPi), as novel molecular-targeted therapy agents that bring benefits to ovarian cancer patients, have been recommended as maintenance therapy for platinum-sensitive recurrent ovarian cancer patients and postoperative maintenance therapy by several clinical guidelines. However, the safety issues, especially the hematological toxicities of the drugs, should be carefully regarded. This review compared the pharmacological characteristics and hematological toxicities of three different PARPi, so as to provide more information of the clinical application for the recurrent ovarian cancer patients.